A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis

被引：0

作者：

Merkel, Peter A. ^{[1
]}

Niles, John ^{[2
]}

Jimenez, Richard ^{[3
]}

Spiera, Robert F. ^{[4
]}

Rovin, Brad H. ^{[5
]}

Bomback, Andrew ^{[6
]}

Pagnoux, Christian ^{[7
]}

Potarca, Antonia ^{[8
]}

Schall, Thomas J. ^{[9
]}

Bekker, Pirow ^{[9
]}

机构：

[1] Univ Penn, Div Rheumatol, Perelman Sch Med, Philadelphia, PA 19104 USA

[2] Massachusetts Gen Hosp, Boston, MA 02114 USA

[3] Univ Washington Med, Northwest Hosp & Med Ctr, Seattle Arthrit Clin, Rheumatol, Seattle, WA USA

[4] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA

[5] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA

[6] Columbia Univ, Med Ctr, New York, NY USA

[7] Univ Toronto, Univ Hlth Network, Mt Sinai Hosp, Div Rheumatol, Toronto, ON, Canada

[8] ChemoCentryx Inc, Mountain View, CA USA

[9] ChemoCentryx, Mountain View, CA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

978

引用

页数：2

共 50 条

[1] C5aR inhibitor on leukocytes exploratory ANCA associated renal vasculitis (CLEAR) clinical trial with orally administered CCX168
Bruchfeld, A.
Schaier, M.
Jadoul, M.
Selga, D.
Szombati, I.
Venning, M.
Hamilton, P.
Ciechanowski, K.
Hugo, C.
Segelmark, M.
Viklicky, O.
Jaen, J.
Schall, T.
Bekker, P.
PRESSE MEDICALE, 2013, 42 (04): : 768 - 769
[2] CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Bekker, Pirow
Jayne, David
Bruchfeld, Annette
Schaier, Matthias
Ciechanowski, Kazimierz
Harper, Lorraine
Jadoul, Michel
Segelmark, Marten
Selga, Daina
Szombati, Istvan
Venning, Michael
Hugo, Christian
van Daele, Paul L.
Viklicky, Ondrej
Potarca, Antonia
Schall, Thomas J.
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S820 - S820
[3] EFFECT OF A SELECTIVE C5AR ANTAGONIST, AVACOPAN (CCX168), ON PLASMA COMPLEMENT LEVELS IN ANCA ASSOCIATED VASCULITIS (AAV)
Bunch, D. O.
Deng, J.
McInnis, E. A.
Bekker, P.
Hillson, J. L.
Schall, T. J.
Jennette, C. J.
Nachman, P.
Deng, J.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 74 - 75
[4] ORAL C5A RECEPTOR ANTAGONIST CCX168 PHASE 2 CLINICAL TRIAL IN ANCA-ASSOCIATED RENAL VASCULITIS
Jayne, D. R.
Bruchfeld, A.
Schaier, M.
Ciechanowski, K.
Harper, L.
Jadoul, M.
Segelmark, M.
Selga, D.
Szombati, I.
Venning, M.
Hugo, C.
Van Daele, P. L.
Viklicky, O.
Potarca, A.
Schall, T. J.
Bekker, P.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 148 - 148
[5] ORAL C5A RECEPTOR ANTAGONIST CCX168 IN A PHASE 2 CLINICAL TRIAL IN ANCA-ASSOCIATED RENAL VASCULITIS
Bekker, Pirow
Potarca, Antonia
Dairaghi, Daniel
Miao, Shichang
Powers, Jay P.
Jaen, Juan C.
Schall, Thomas J.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 419 - 420
[6] SUCCESSFUL STEROID REPLACEMENT IN ANCA-ASSOCIATED VASCULITIS WITH C5A RECEPTOR INHIBITOR CCX168 IN PHASE 2 RANDOMISED TRIAL (CLEAR)
Jayne, David
Bruchfeld, Annette
Harper, Lorraine
Schaier, Matthias
Venning, Michael
Hamilton, Patrick
Burst, Volker
Grundman, Franziska
Jadoul, Michel
Szombati, Istvan
Tesar, Vladimir
Segelmark, Marten
Potarca, Antonia
Schall, Thomas J.
Bekker, Pirow
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 45 - 45
[7] PHASE 2 RANDOMISED TRIAL OF ORAL C5A RECEPTOR ANTAGONIST CCX168 IN ANCA-ASSOCIATED RENAL VASCULITIS
Jayne, David R. W.
Bruchfeld, Annette
Schaier, Matthias
Ciechanowski, Kazimierz
Harper, Lorraine
Jadoul, Michel
Segelmark, Marten
Selga, Daina
Szombati, Istvan
Venning, Michael
Hamilton, Patrick
Hugo, Christian
Van Daele, Paul L. A.
Viklicky, Ondrej
Potarca, Antonia
Schall, Thomas J.
Bekker, Pirow
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 27 - 27
[8] CLINICAL DOSE SELECTION OF THE C5A RECEPTOR ANTAGONIST CCX168 FOR THE PHASE 2 ANCA-ASSOCIATED RENAL VASCULITIS CLINICAL TRIAL (THE CLEAR TRIAL)
Dairaghi, Daniel
Johnson, Daniel
Leleti, Manmohan
Miao, Shichang
Xiao, Hong
Jennette, J. Charles
Powers, Jay P.
Seitz, Lisa
Wang, Yu
Jaen, Juan C.
Schall, Thomas J.
Bekker, Pirow
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 401 - 402
[9] CHARACTERIZATION OF THE NOVEL C5AR ANTAGONIST CCX168, A POTENTIAL THERAPEUTIC FOR ANCA-VASCULITIS, RHEUMATOID ARTHRITIS, AND OTHER AUTOIMMUNE DISORDERS
Powers, J. P.
Bekker, P. J.
Dairaghi, D. J.
Jennette, J. C.
Johnson, D. A.
Leleti, M.
Miao, S.
Seitz, L. C.
Wang, Y.
Xiao, H.
Schall, T. J.
Jaen, J. C.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 124 - 124
[10] Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
Jayne, David R. W.
Bruchfeld, Annette N.
Harper, Lorraine
Schaier, Matthias
Venning, Michael C.
Hamilton, Patrick
Burst, Volker
Grundmann, Franziska
Jadoul, Michel
Szombati, Istvan
Tesar, Vladimir
Segelmark, Marten
Potarca, Antonia
Schall, Thomas J.
Bekker, Pirow
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (09): : 2756 - 2767

← 1 2 3 4 5 →